POMC and neoplasm: A reduction of tumor volume with pasireotide treatment has been documented in patients with CD [24, 32] and a case report of a patient with Nelson’s syndrome treated with pasireotide LAR [27]; similar to our findings, the reduction in ACTH in this case report was evident early, within 1 month of treatment with improvement of skin hyperpigmentation.